The three core advantages of tesiparatide: scientific data reveals why it is popular around the world

June 26, 2025

According to the global diabetes drug sales data in 2023, Tirzepatide has occupied 35% of the GLP-1 receptor agonist market share in just 18 months after its launch, while the growth rate of Semaglutide has dropped to 12% during the same period. This market change is due to three breakthrough advantages:

Advantage 1: Dual target mechanism brings better metabolic regulation

🧬 Differences in mechanism of action

drug	Target	Pathway
Semaglutide	GLP-1 receptor monoagonist	Activates only the glucagon-like peptide-1 pathway
Tesiparatide	GIP/GLP-1 dual agonists	Synchronous regulation of glucose-dependent insulinotropic polypeptide

Clinical evidence (SURPASS-2 study):

● Glycemic control : HbA1c decreased by 2.4% in the tesiparatide 15 mg group vs 1.9% in the semaglutide 1 mg group

● β-cell function : HOMA-β index improved by 68% (only 41% in the simepreneur group)

● 24-hour blood sugar curve : fluctuation range reduced by 35 %

Advantage 2: Excellent weight loss effect

📊 Weight loss data comparison (STEP vs SURPASS study)

index	Tesiparatide 15mg	Semaglutide 2.4mg	Advantage
68-week weight loss	-15.6kg	-12.4kg	+26%
Waist circumference reduction	-12.1cm	-9.3cm	+30%
≥15% weight loss	52%	36%	+44%

Key findings :

● Visceral fat reduction increased by 42% (MRI detection)

● Lean body mass retention rate increased by 3.2 percentage points

Weight plateau occurs 8-12 weeks later

Advantage 3: More comprehensive metabolic improvement

🌟 Comparison of benefits from multiple systems

1. Liver Health

● Fatty liver improvement rate: 62% vs 45% (FibroScan test)

● Decrease in liver inflammation marker ALT: 47% vs 32%

2. Cardiovascular protection

Systolic blood pressure reduction: 8.2 mmHg versus 5.7 mmHg

Improved arterial stiffness: CAVI index change -0.8 vs -0.3

3. Convenience of medication

● The target dose is used for a short period of 2 to 4 weeks

Injection pain scores were 30% lower

💡 Priority selection suggestions for three groups of people

1. Patients with severe insulin resistance (HOMA-IR>5)

2. The dual mechanism is more effective in improving the obesity of people with sensitive BMI ≥ 35

3. The additional 4-5kg weight loss difference is clinically significant for diabetic patients with fatty liver ( Liver fat content decreased by 17 percentage points)